Akums gets DCGI approval to launch Lobeglitazone for diabetes treatment in India
It offers a number of advantages including a higher safety profile, higher effectiveness in lower dosage, lower risk of hypoglycemia, and improved pancreatic beta-cell function
Akums Drugs and Pharmaceuticals has launched an antidiabetic drug, ‘Lobeglitazone’, to improve pancreatic beta-cell function in type 2 diabetic patients.
Akums has become the first CDMO to launch Lobeglitazone tablets for commercial consumption, informed a company statement.
The statement said, “The drug was formulated for type 2 diabetics who secrete insulin but have poor insulin sensitivity in their organs, making them less able to utilise insulin. Lobeglitazone has a relatively low risk of hypoglycemia. The unique formulation was manufactured to improve insulin resistance rather than force its release from the pancreas.”
“The tablet has been proven to reduce blood sugar levels, improve lipid and liver profiles, and lower haemoglobin A1C (HbA1C) levels,” said Sanjeev Jain, MD, Akums.
Sandeep Jain, MD, Akums said, “With the Lobeglitazone tablets, what we’ve put together is a unique formulation that tackles type 2 diabetes by addressing the root causes in a more effective way; by affecting the relationship between the PPAR gamma, insulin, and fat cells to improve insulin resistance, among other things.”
The statement informed, “Lobeglitazone is a film-coated tablet made up of Lobeglitazone Sulfate equivalent to Lobeglitazone at 0.5 mg. It is approved by the Drugs Controller-General of India (DCGI) and offers a number of advantages, including higher safety profile, higher effectiveness in lower dosage, lower risk of hypoglycemia, and improved pancreatic beta-cell function, among others.”
The company also plans to introduce more fixed-dose drug combinations (FDCs) in the future specifically for the treatment and management of diabetes.